Experimental vaccine to be used against Ebola outbreak in the DRC

Merck's experimental Ebola vaccine will get a real-world test.
Merck's experimental Ebola vaccine, shown here during testing in 2015, will be used in the Democratic Republic of the Congo later this week. Source: John Moore/Getty Images

A campaign to vaccinate people at risk of developing Ebola in the latest outbreak in the Democratic Republic of the Congo could begin by the end of this week, Tedros Adhanom Ghebreyesus, the director-general of the World Health Organization, said Sunday.

Tedros said the government of the DRC has formally asked to use an being developed by Merck. The WHO has a stockpile of 4,300 doses of the vaccine in Geneva; the company also has 300,000 doses of the vaccine stockpiled

Vous lisez un aperçu, inscrivez-vous pour en lire plus.

Plus de STAT

STAT1 min de lectureMedical
STAT Plus: Pharmalittle: Trump At High Risk Of Serious Covid-19 Illness; Gilead To Resume Distribution Of Remdesivir
President Trump announced on Twitter early Friday morning that he contracted the coronavirus and is now in quarantine.
STAT1 min de lecture
STAT Plus: Pharmalittle: Fewer Americans Are Willing To Get A Covid-19 Shot When It’s First Available; Remdesivir May Not Be A Big Seller
The share of Americans who say they are likely to get a Covid-19 vaccine as soon as it’s available is dropping — and the decline is more pronounced among Black…
STAT1 min de lectureMedical
STAT Plus: Pharmalittle: Study Finds Remdesivir Fails To Prevent Covid-19 Deaths; Trump’s $200 Discount Drug Cards Hit Snags
A WHO study concluded that remdesivir appeared to have little or no effect on 28-day mortality or length of hospital stays for Covid-19 patients.